Last year, Janssen Pharmaceutica opened a new research center, the Dr. Paul Janssen Research Center, a project costing 68 million euros and providing accommodation for 300 investigators. This building is the latest realization in a package of approximately 200 million euros worth of capital expenditure on five new research buildings in the last three years and marks the definitive establishment of basic drug research by Johnson & Johnson in Belgium. The research division was internationally integrated a few years ago under the name Johnson & Johnson Pharmaceutical Research & Development. The Belgian branch is a division of Janssen Pharmaceutica and is led by
Dr. Didier de Chaffoy. Today the research division in Beerse numbers 1400 employees.

Today, thanks in part to the steady growth and innovatory medicines of Janssen Pharmaceutica, the Pharmaceutical Group of Johnson & Johnson is the fourth biggest drug company in the world. The trading results of Janssen are traditionally excellent. In 2003, sales totaled 1876 million euros, while the net profit amounted to 355 million euros. The workforce numbered 4386 employees, and spending on Research & Development came to 868 million euros. Meanwhile, the research pipeline is filled with substances for treating cancer, central nervous system disorders, tuberculosis, internal diseases and pain treatment. It should also be mentioned that Janssen has a tradition of sustainable enterprise, a field in which it plays a pioneering role.
Last year, for the first time, the firm presented a Sustainability Report.

For more info: click on "Trends".